Seamus Fernandez
Stock Analyst at Guggenheim
(3.44)
# 1,000
Out of 4,667 analysts
88
Total ratings
48.89%
Success rate
5%
Average return
Main Sectors:
Stocks Rated by Seamus Fernandez
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Initiates: Buy | $33 | $15.12 | +118.25% | 1 | Nov 8, 2024 | |
| MRK Merck & Co. | Maintains: Buy | $137 → $130 | $97.44 | +33.42% | 13 | Nov 6, 2024 | |
| GSK GSK | Downgrades: Neutral | n/a | $33.35 | - | 2 | Oct 31, 2024 | |
| RYTM Rhythm Pharmaceuticals | Initiates: Buy | $70 | $59.36 | +17.92% | 1 | Oct 21, 2024 | |
| TENX Tenax Therapeutics | Initiates: Buy | $16 | $4.77 | +235.43% | 1 | Oct 14, 2024 | |
| MBX MBX Biosciences | Initiates: Buy | $44 | $16.24 | +170.94% | 1 | Oct 8, 2024 | |
| LLY Eli Lilly | Maintains: Buy | $884 → $1,030 | $753.41 | +36.71% | 14 | Aug 16, 2024 | |
| RVNC Revance Therapeutics | Downgrades: Neutral | n/a | $3.80 | - | 1 | Aug 12, 2024 | |
| HLVX HilleVax | Downgrades: Neutral | n/a | $1.79 | - | 3 | Jul 8, 2024 | |
| ALT Altimmune | Downgrades: Neutral | n/a | $8.05 | - | 3 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $44 → $91 | $45.04 | +102.04% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $56 → $55 | $4.55 | +1,108.79% | 1 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | n/a | $16.17 | - | 2 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $12.60 | +153.97% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $65 | $85.96 | -24.38% | 2 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $32.71 | +52.86% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $57.88 | - | 12 | Oct 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $105.27 | - | 2 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $103.09 | - | 6 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.23 | - | 1 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $27 | $85.64 | -68.47% | 4 | Nov 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $54 | $3.96 | +1,263.64% | 1 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $45 | $26.40 | +70.45% | 3 | Mar 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $36 → $38 | $63.20 | -39.87% | 6 | Feb 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $35 → $38 | $24.94 | +52.37% | 3 | Jan 31, 2018 |
Cidara Therapeutics
Nov 8, 2024
Initiates: Buy
Price Target: $33
Current: $15.12
Upside: +118.25%
Merck & Co.
Nov 6, 2024
Maintains: Buy
Price Target: $137 → $130
Current: $97.44
Upside: +33.42%
GSK
Oct 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $33.35
Upside: -
Rhythm Pharmaceuticals
Oct 21, 2024
Initiates: Buy
Price Target: $70
Current: $59.36
Upside: +17.92%
Tenax Therapeutics
Oct 14, 2024
Initiates: Buy
Price Target: $16
Current: $4.77
Upside: +235.43%
MBX Biosciences
Oct 8, 2024
Initiates: Buy
Price Target: $44
Current: $16.24
Upside: +170.94%
Eli Lilly
Aug 16, 2024
Maintains: Buy
Price Target: $884 → $1,030
Current: $753.41
Upside: +36.71%
Revance Therapeutics
Aug 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.80
Upside: -
HilleVax
Jul 8, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.79
Upside: -
Altimmune
Apr 29, 2024
Downgrades: Neutral
Price Target: n/a
Current: $8.05
Upside: -
Mar 5, 2024
Maintains: Buy
Price Target: $44 → $91
Current: $45.04
Upside: +102.04%
Aug 15, 2023
Maintains: Buy
Price Target: $56 → $55
Current: $4.55
Upside: +1,108.79%
Jul 14, 2023
Maintains: Buy
Price Target: n/a
Current: $16.17
Upside: -
Mar 7, 2023
Initiates: Buy
Price Target: $32
Current: $12.60
Upside: +153.97%
Feb 28, 2023
Maintains: Buy
Price Target: $66 → $65
Current: $85.96
Upside: -24.38%
Feb 28, 2023
Initiates: Buy
Price Target: $50
Current: $32.71
Upside: +52.86%
Oct 10, 2022
Downgrades: Neutral
Price Target: n/a
Current: $57.88
Upside: -
May 31, 2022
Upgrades: Buy
Price Target: n/a
Current: $105.27
Upside: -
Feb 25, 2020
Downgrades: Neutral
Price Target: n/a
Current: $103.09
Upside: -
Feb 3, 2020
Downgrades: Neutral
Price Target: n/a
Current: $5.23
Upside: -
Nov 15, 2018
Initiates: Outperform
Price Target: $27
Current: $85.64
Upside: -68.47%
Mar 13, 2018
Maintains: Outperform
Price Target: $56 → $54
Current: $3.96
Upside: +1,263.64%
Mar 8, 2018
Maintains: Market Perform
Price Target: $60 → $45
Current: $26.40
Upside: +70.45%
Feb 6, 2018
Maintains: Market Perform
Price Target: $36 → $38
Current: $63.20
Upside: -39.87%
Jan 31, 2018
Maintains: Market Perform
Price Target: $35 → $38
Current: $24.94
Upside: +52.37%